Pyxis Oncology
Sara Lewandowski Hollander is a highly skilled scientist with extensive experience in translational medicine and biomedical research. Currently serving as Senior Scientist in Translational Medicine at Pyxis Oncology since August 2020, Sara has previously held multiple roles in the same field. At Boston University, as a Postdoctoral Fellow, Sara established innovative ex vivo culture techniques for murine lung progenitors, leading to significant advancements in cell identity retention and yield. Notable achievements include the identification of key transcription factors in lung development, successful management of single cell RNA-sequencing projects, and co-authoring multiple publications. Sara's earlier research at UMass Medical School contributed to insights into cardiac development and deacetylase functions. Educational qualifications include a PhD in Biomedical Sciences from UMass Chan Medical School and a BS in Biology from SUNY Geneseo.
Pyxis Oncology
2 followers
Pyxis Oncology is advancing a differentiated portfolio of potent biologics, including antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies with the potential to help patients suffering from difficult-to-treat cancers.